Tirzepatide vs Semaglutide
Dual Agonist vs Single Agonist — The Science Behind the Brand Names
Forget the brand names for a moment. Semaglutide (Ozempic/Wegovy) activates one receptor. Tirzepatide (Mounjaro/Zepbound) activates two. That structural difference drives measurably better weight loss outcomes in head-to-head trials and explains why the mechanism comparison matters to anyone choosing between them.
Mechanism of Action: Side by Side
Semaglutide (GLP-1 Agonist)
- →Targets GLP-1 receptors only
- →Mimics incretin hormone released after eating
- →Stimulates insulin secretion (glucose-dependent)
- →Suppresses glucagon → lowers hepatic glucose output
- →Acts on hypothalamus to reduce appetite
- →Slows gastric emptying → prolongs satiety
- →Half-life ≈7 days (once-weekly dosing)
Tirzepatide (GIP + GLP-1 Dual Agonist)
- →Targets both GIP and GLP-1 receptors simultaneously
- →GIP agonism enhances insulin sensitivity in adipose tissue
- →GIP activity may reduce GI side effects vs GLP-1 alone
- →Dual signalling drives deeper weight loss in trials
- →Also suppresses appetite via hypothalamic pathways
- →Slows gastric emptying similarly to semaglutide
- →Half-life ≈5 days (once-weekly dosing)
Head-to-Head Comparison
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor targets | GLP-1 only | GIP + GLP-1 |
| Brand names (injectable) | Ozempic (T2D), Wegovy (obesity) | Mounjaro (T2D), Zepbound (obesity) |
| FDA approval (obesity) | Wegovy — June 2021 | Zepbound — November 2023 |
| Max dose | 2.4 mg weekly (Wegovy) | 15 mg weekly |
| Weight loss — Phase 3 | ~15% (STEP-1, Wegovy 2.4 mg) | ~21% (SURMOUNT-1, 15 mg) |
| HbA1c reduction | ~1.8–2.2% | ~2.0–2.3% |
| Nausea incidence | ~44% (Wegovy dose) | ~31% (15 mg) |
| CV outcome trial | SUSTAIN-6 / SELECT (positive) | SURMOUNT-MMO (ongoing) |
| Oral formulation | Yes (Rybelsus, T2D only) | Oral in development |
| Compounded available | Yes (FDA shortage list, check date) | Limited — check FDA status |
Data from prescribing information, STEP-1 (Wilding et al., NEJM 2021) and SURMOUNT-1 (Jastreboff et al., NEJM 2022). [1, 2]
Weight Loss: The Numbers
Semaglutide 2.4 mg (STEP-1)
14.9%
Mean weight loss at 68 weeks vs 2.4% placebo in STEP-1 (N=1961 adults with obesity).
Tirzepatide 15 mg (SURMOUNT-1)
20.9%
Mean weight loss at 72 weeks vs 3.1% placebo in SURMOUNT-1 (N=2539 adults with obesity).
Absolute difference (trial estimate)
~6%
Extra mean weight loss with tirzepatide. In the SURPASS-STEP head-to-head trial (2025), tirzepatide was superior to semaglutide.
Which Drug Is Right for You?
For maximum weight loss in people with obesity or overweight, tirzepatide 15 mg shows greater efficacy than semaglutide 2.4 mg in both individual trials and the 2025 head-to-head SURPASS-STEP trial. If primary weight loss is the goal and your prescriber has no contraindications, tirzepatide is the evidence-based choice.
Semaglutide has longer real-world data (approved 2017 for T2D, 2021 for obesity), a proven cardiovascular outcome trial (SUSTAIN-6, SELECT), and an oral formulation (Rybelsus). If cardiovascular risk reduction is a priority alongside glycaemic control, semaglutide's SELECT outcome data is currently more established than tirzepatide's (SURMOUNT-MMO pending).
GI tolerability: some clinicians note tirzepatide causes less nausea in practice due to GIP modulating GLP-1 side effects, though both drugs are well-tolerated by most patients when dosed with the standard slow escalation.
Track Either Drug in Shotlee
Shotlee supports dose logging, weight tracking, side effect recording, and lab snapshots for both semaglutide and tirzepatide. If you switch between them, your historical baseline data stays intact for comparison.
Choose Based on Your Goal
Maximum weight loss
Established CV data
Oral formulation now
Lower GI side effects
Insurance / cost
T2D + weight management combo
Tirzepatide vs Semaglutide: Frequently Asked Questions
By weight loss efficacy, yes. Tirzepatide 15 mg achieved ~20.9% mean weight loss in SURMOUNT-1 vs ~14.9% for semaglutide 2.4 mg in STEP-1. The 2025 SURPASS-STEP head-to-head trial confirmed tirzepatide's superiority for weight reduction. For cardiovascular outcomes, semaglutide has stronger published trial data (SELECT, 2023).
Mounjaro (tirzepatide) targets both GIP and GLP-1 receptors. Ozempic (semaglutide) targets GLP-1 only. Mounjaro is approved for type 2 diabetes; Zepbound (same molecule) is approved for obesity. Ozempic is approved for type 2 diabetes; Wegovy (same molecule, higher dose) is approved for obesity.
Yes, with prescriber guidance. There is no mandatory washout period between the two. Common practice is to start tirzepatide at the lowest dose (2.5 mg) regardless of the semaglutide dose previously used, then escalate normally. Track both drugs in Shotlee so your prescriber can compare your response to each.
Both cause similar GI side effects (nausea, vomiting, constipation, diarrhoea). Clinical trial data suggests slightly lower nausea rates with tirzepatide (31% vs 44% at weight-loss doses). Individual tolerance varies considerably. Track your side effects in Shotlee to identify patterns.
Insurance coverage varies widely. For obesity (without type 2 diabetes): Zepbound and Wegovy have the broadest obesity coverage but many plans still exclude them. For type 2 diabetes: Mounjaro and Ozempic have better coverage. Manufacturer savings programs (Lilly's and Novo's) can reduce costs for eligible patients.
References
- [1]Clinical TrialWilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." N Engl J Med. 2021;384(11):989-1002.
- [2]Clinical TrialJastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." N Engl J Med. 2022;387(3):205-216.
- [3]Clinical TrialFrias JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)." N Engl J Med. 2021;385(6):503-515.
- [4]Clinical TrialLincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)." N Engl J Med. 2023;389(24):2221-2232.
- [5]Clinical TrialMarso SP, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)." N Engl J Med. 2016;375(19):1834-1844.
Track Whichever GLP-1 You Use
Shotlee supports both semaglutide and tirzepatide dose logging, weight tracking, and side effect recording — completely free.
🚀 Use Shotlee for Free